新辅助化疗对乳腺癌ER、PR和EphA2表达的影响及意义

Effect and Clinical Significance of Neoadjuvant Chemotherapy on Expression of ER,PR and EphA2 in Breast Cancer

摘要: 目的研究乳腺癌中ER、PR和EphA2的表达在新辅助化疗前后的变化及临床意义。方法采用免疫组织化学SP法检测新辅助化疗前后ER、PR和EphA2在52例乳腺癌的表达情况。结果 ER、PR和EphA2的表达均与疗效相关；新辅助化疗后EphA2的阳性表达率显著下降（P＜0.05）；ER、PR的阳性表达率则无明显变化（P＞0.05）。结论新辅助化疗能抑制肿瘤细胞增殖，促进肿瘤细胞凋亡，显著降低EphA2的阳性表达，而对ER、PR的表达无显著影响。

Abstract: Objective To study the influence of neoadjuvant chemotherapy on expression of ER、PR and EphA2 in breast cancer and their clinical significance. Methods The expressions of ER、PR and EphA2 of 52 patients with breast cancer were investigated by SP immunohistochemical method before and after Neoadjuvant Chemotherapy. Results The expressions of ER、PR and EphA2 were significantly related to treatment response (P<0.05).The positive expression rate of EphA2 after neoadjuvant chemotherapy was significantly lower than that before the treatment(P<0.05),but the difference of ER,PR before and after neoadjuvant chemotherapy were insignificant(P＞0.05). Conclusion Neoadjuvant chemotherapy could inhibit tumor proliferation and induce tumor cell apoptosis，and significantly decrease the expression of EphA2,but it could not reduce the expression of ER and PR significantly.